Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 7/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | LIPC | P11150 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744828 | 1.00 | NAMPT (0.44) | NAMPTGRM5GRM1TLR7CDK9 | |
| SCHEMBL30702789 | 0.90 | TNF (0.43) | NAMPTGRM5GRM1CDK9CCNT1 | |
| SCHEMBL30702786 | 0.90 | TNF (0.43) | NAMPTGRM5GRM1CDK9CCNT1 | |
| SCHEMBL21966184 | 0.87 | NAMPT (0.45) | NAMPTGRM5GRM1TNK2GPR119 | |
| SCHEMBL29197645 | 0.87 | NAMPT (0.44) | NAMPTGRM5GRM1CDK9CCNT1 | |
| SCHEMBL29744746 | 0.87 | PDE10A (0.44) | NAMPTGRM5GRM1CDK9CCNT1 | |
| SCHEMBL23538333 | 0.87 | PDE10A (0.44) | NAMPTGRM5GRM1CDK9CCNT1 | |
| SCHEMBL31583549 | 0.86 | GRM5 (0.44) | NAMPTGRM5GRM1CDK9CCNT1 | |
| SCHEMBL30511793 | 0.85 | PDK4 (0.45) | NAMPTGRM5GRM1TLR7CDK9 | |
| SCHEMBL29197745 | 0.85 | PDK4 (0.45) | NAMPTGRM5GRM1TLR7CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| CN-118344370-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20230145336-A1 | BRAF DEGRADERS | C4 THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| CN-115996719-A | BRAF degradation agent | C4医药公司 | 2023-04-21 | — | — | CN | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| CN-114901277-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021255212-A1 | BRAF DEGRADERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | NAMPT 4414/4885GRM5 3833/4885GRM1 1349/4885 |
| US-12486253-B2 | Therapeutics for the degradation of mutant BRAF | BRAF, NRAS, KRAS | NAMPT 819/4885GRM5 4505/4885GRM1 4618/4885 |
| US-20230145336-A1 | BRAF DEGRADERS | BRAF, NRAS, RAF1 | NAMPT 656/4885GRM5 4299/4885GRM1 4581/4885 |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | NAMPT 4204/4885GRM5 2393/4885GRM1 3294/4885 |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | NAMPT 4204/4885GRM5 2393/4885GRM1 3294/4885 |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | NAMPT 4204/4885GRM5 2393/4885GRM1 3294/4885 |
| US-20250115580-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | NAMPT 819/4885GRM5 4505/4885GRM1 4618/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | NAMPT 4878/4885GRM5 3445/4885GRM1 3124/4885 |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | NAMPT 4204/4885GRM5 2393/4885GRM1 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.